BioAtla (BCAB) Return on Sales (2020 - 2025)

BioAtla's Return on Sales history runs 5 years deep, the most recent figure standing at 0.05% for Q4 2025.

• On a quarterly basis, Return on Sales rose 43.0% year-over-year to 0.05% in Q4 2025; TTM through Dec 2025 was 0.05%, a 42.0% increase from a year earlier, with the FY2025 full-year figure at 0.87%, down 71.0% from the prior year.
• Return on Sales climbed to 0.05% in Q4 2025 per BCAB's latest filing, from 0.07% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q3 2024 and bottomed at 8.96% in Q3 2023.
• The 4-year median for Return on Sales is 1.43% (2021), against an average of 2.39%.
• Across the five-year window, Return on Sales sank 377 bps in 2021 and soared 894 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 4.49% in 2021, then sank by 99 bps to 8.96% in 2023, then soared by 95 bps to 0.48% in 2024, then jumped by 90 bps to 0.05% in 2025.
• Per Business Quant, the three latest BCAB Return on Sales figures stand at 0.05% (Q4 2025), 0.07% (Q3 2025), and 0.48% (Q4 2024).